10/10/2017. Disclosure
|
|
- Eustace Kelley
- 5 years ago
- Views:
Transcription
1 Disclosure Ronna Hauser, Vice President, Pharmacy Affairs, NCPA declares no conflicts of interest or financial interest in any product or service mentioned in this program, including grants, employment, gifts, stock holdings, and honoraria. 1
2 Learning Objectives Discuss the implementation timeline for USP 800. Summarize the inspection trends and how to prepare for an inspection. Outline the main protocols and assess budget impact for compliance. The 2018 Readiness Check Up: The Top 5 Things for Compounders to Keep on Your Radar Ronna B. Hauser, PharmD VP, Pharmacy Affairs NCPA 2
3 NCPA Protecting Your Right to Compound NCPA Compounding Committee guides our positions (focused on 503A) NCPA Active participant in FDA Listening Sessions, PCAC Bulk Drug Substance Nominations, DQSA stakeholder coalition NCPA Top Issues of Concern Office use compounding MOU Inspections USP Monograph Issue Essential Copies Creation of bulk positive list PCAC Processes and Makeup NCPA Compounding Committee Members Chair Rich Moon Board Liaison Lea Wolsoncroft Members Donnie Calhoun A.J. Day Cheri Garvin Kelly Selby Elaine Ladd Jake Olson David Rochefort Chris Geronsin Student Ralph Galega 3
4 Top 5 Things for Compounders to Keep on Your Radar 1. FDA Implementation of DQSA/Washington D.C. Activity 2. FDA/State Board of Pharmacy Roles 3. FDA PCAC/Creation of Compounding Lists 4. FDA Inspections Update 5. Important USP Updates/Tips for Success What s in Section 503A Prescription Requirement Anticipatory Compounding Allowable bulk drug products (APIs) positive list Allowable inactive ingredients Negative list Essential copies of commercially available medication Demonstrably difficult list MOU for interstate commerce of distributed compounded products Pharmacy Compounding Advisory Committee (PCAC) 4
5 What s NOT in Section 503A Veterinary Compounding Exemptions provided in 503A only pertain to the manufacture of human drug products (Sections 501(a)(2)(B), 502(f)(1), and 505). FDA s website Information on Compounding : Section 503A describes the conditions under which certain compounded human drug products are entitled to exemptions Human drug compounding/products mentioned many times in guidances. FDA s notice on inspections ( ): (i.e., human drug compounders that are not registered with FDA as outsourcing facilities under section 503B). Thank You! 5
6 Disclosure Cynthia Blankenship, Esq, Executive Vice President International Academy of Compounding Pharmacists declares no conflicts of interest or financial interest in any product or service mentioned in this program, including grants, employment, gifts, stock holdings, and honoraria. 6
7 Regulatory Outlook: FDA Implementation of the DQSA FDA utilizing guidance/policy approach instead of formal rulemaking process but implementing the guidance/policy as FINAL. 20 guidance documents Some examples of guidance/policy: Insanitary Conditions Commercially Available (503A and 503B) 503A Prescription Requirement Hospital and Health System Compounding Repackaging (503A and 503B) Biologics cgmps for 503B Interim/Ongoing Guidance/Policy The Pharmacy Compounding Advisory Committee (PCAC) and the Lists. The DQSA charges FDA and the PCAC with creating three lists: two negative lists and one positive list. PCAC meets about three times per year, considers about six bulk drug products each meeting, but PCAC s vote is NOT binding. Bulk Substances Nominations Categories 1, 2, and 3 Demonstrably Difficult to Compound Withdrawn and Removed (Final Rule/Proposed Rule) Full List: ng/ucm htm 7
8 Regulatory Outlook: FDA Implementation of Office Use Compounding 503A Final Guidance 503A Office-use Compounding; Comments due July 2016; and Finalized on December 28, 2016 Guidance prohibits 503A pharmacies from providing office-use compounding despite State law. While only guidance, FDA is implementing complete prohibition of 503A pharmacies in Warning Letters stating solely based on the fact the pharmacy provides compounded medications to health care facilities for administration to patients, the pharmacy is in violation of the Food Drug and Cosmetic Act. FDA drew a line between anticipatory compounding and office-use. 503A Draft Guidance Hospital and Health System Compounding under the FDCA Released April 15, 2016; Comments due July 18, 2016 Recognizes some hospitals and health systems compound drugs only for use in the hospitals in which the pharmacy is located while other hospitals and health systems distribute to other facilities within their health system (i.e. clinics, infusion centers, long-term care facilities and others purchase compounds from 503Bs. If a hospital or health systems do not meet the three requirements provided in the draft guidance, then it is bound by the general prescription and anticipatory compounding requirements found within 503A 8
9 503A Draft Guidance Hospital and Health System Compounding under the FDCA To qualify for the exemptions under 503A to cgmps, labeling, and drug approval process, FDA states it does not intend to take action if: The drug products are distributed only to healthcare facilities that are owned and controlled by the same entity AND that are located within 1 mile radius of the compounding pharmacy; Only administered within the healthcare facility to patients within the healthcare facility, pursuant to a patient specific prescription or order; and Meet all other provisions of 503A. 503A Draft Guidance Hospital and Health System Compounding under the FDCA If a hospital or health system cannot meet the exemption requirements, then the draft guidance suggests that a hospital or health system may register as a 503B Outsourcing Facility or obtain compounded medications from a 503B Outsourcing Facility. The draft guidance also states that all hospitals and health system compounders that elect to register with FDA as Outsourcing Facilities must comply with all of the provisions of 503B. The draft guidance also states that drugs compounded by Outsourcing Facilities are not exempt from cgmps and will be inspected by FDA on a risk-based schedule. Once a facility registers as 503B, all the facility's compounded drugs must be compounded in accordance with 503B. Those that should not register: if the facility s activities only include repackaging, compounding non-sterile or animal drugs, or mixing, diluting or repackaging biological products subject to licensure under section 351 of the PHS Act. 9
10 Regulatory Outlook: FDA Implementation of the MOU Draft MOU Contents 503A language regarding the MOU State s choice Lower limit/cap set by statute 5% Upper limit/cap determined by FDA 30% Distribution vs. Dispense and FDA s change of definitions Language is distinguished within section 503A of DQSA Language distinguished within the Controlled Substances Act FDA s interpretation and what this means FDA Efforts with State Boards of Pharmacy Appropriate agencies of the State will investigate complaints received relating to human drug products compounded by a pharmacist, pharmacy, or physician located in the State of [insert State] and distributed outside the State. Any investigations performed by the State of [insert State] under this MOU will include, but are not limited to (1) determination of whether there is a potential public health risk or safety concern associated with the compounded human drug product; and (2) confirmation that any risk or safety concern associated with the product is adequately contained (i.e., there is no ongoing risk to the public). 10
11 FDA Efforts with State Boards of Pharmacy State required to take appropriate action. State required to notify FDA via within 72 hours of receiving any complaint related to compounding. State maintains all records and State must review all pharmacy records. How does this work with Section 704 of the FDCA records exemption? Parties must share information. FDA agrees information will not be disclosed. How does this work with FOIA? Regulatory Outlook: FDA Implementation of the PCAC Lists FDA and PCAC Lists Bulk Drug Substances (Positive List) Withdrawn and Removed List (Do Not Compound List) Demonstrably Difficult (Do Not Compound List) 11
12 Pharmacy Compounding Advisory Committee (PCAC) One current vacancy Efforts to get Stakeholders on the PCAC Nomination Process and Support Letters Congressional PCAC Letters PCAC FY 2018 Appropriations Request More stakeholder input/members that have diverse, recent, and actual experience with compounding More involvement of stakeholders during the meetings Formal Rulemaking process for all three lists Inspection Outlook: Current trends of FDA Inspections and Findings FDA aggressively inspecting - Increase in ALL inspections including hospitals and health systems Compounding - issuing Form 483s and Warning Letters for compounding medications The FDA Compounding: Inspections, Recalls, and other Actions web page lists 6 recent 483s for hospital pharmacies 15 Form 483s were just issued to hospitals and health systems for Medical device MedWatch Reports Result: 483s, Warning Letters, fines, recalls, cease sterile production and media coverage 12
13 FDA Notice of Change in Inspection Policy Published in July 2016, effective August 1, 2016 Required preliminary determination from inspectors All facilities will be held to insanitary conditions Many questions still exist How will Insanitary conditions be determined and cited within the 483s and Warning Letters? How will status of facility be determined? Will the Section 704 records exemption be preserved? What is the inspection standard? Stakeholders Efforts Congressional Bipartisan Office-Use Letters Stewart/Cuellar Letter = 60 bipartisan signatures Stewart/Carter Letter = 65 bipartisan signatures Congressional MOU Letters and Comments PCAC Letters and Comments Congressional hearing questions to FDA and HHS 13
14 Stakeholder s Efforts Questions during Confirmation of Commissioner Gottlieb Congressional Questions for the Record Appropriations Report Language (chart with comparison of all language for FY16-FY18) Federal Legislation (HR 2871) Congressional Recess Meeting Co-Host Other Local Events Congressional Briefing in Washington, DC Congressional Meetings with Commissioner Gottlieb Congressional Dear Colleagues in Follow-up to the Appropriations Effort Congressional Letters RE FDA third category for 503As to register as 503B DQSA fix legislation HR2871 Preserving Patient Access to Compounded Medications Act of 2017 Bipartisan - Griffith(VA)/Cuellar(TX) Office-use clarification of state authority to allow office-use MOU Removes dispense from the MOU Inspection authority records exemption for compounding pharmacists Registration exemption for compounding pharmacists Monograph fixes dietary supplements PCAC requirements Regulation formal rulemaking process with stakeholder input and FDA responses in rules 14
15 Next Steps We Need YOUR Help! Now that HR 2871 legislation has been introduced even more grassroots is necessary Need additional bill cosponsors in House Need companion Senate bill Patient Advocacy Website It s Launched! Please send patients, prescribers and pharmacists here! Contains Voter Voice grassroots capabilities Allows sharing of stories about patient access with Congress 150,000 advocates so far! Check it out! Let your prescribers and patients know about the bill! Thank You! 15
16 Cynthia Blankenship, Esq Executive Vice President International Academy of Compounding Pharmacists 16
17 Disclosure Jon Pritchett, Pharm.D., RPh., Associate Director, Pharmacy, Accreditation Commission for Healthcare declares no conflicts of interest or financial interest in any product or service mentioned in this program, including grants, employment, gifts, stock holdings, and honoraria. <800> Hazardous Drugs Handling in Healthcare Settings Published February 1, 2016 Implementation July 1, Implementation by who?... 17
18 Who enforces USP? State Board of Pharmacy Acceptance 12/50 states YES Under review in many states Proposed implementation: Partial adoption Delayed implementation Task force project Apply to sterile only? *Information provided courtesy of NASPA, current as of 8/9/
19 Federal Agencies and Civil Liability HD deficiencies have been mentioned in some FDA 483s OSHA OSHA Technical Manual Section VI: Chapter 2, Controlling Occupational Exposure to Hazardous Drugs has been archived and replaced New document contains: 209 references to USP 124 references to 800 Liability? The easi(er) things to do: Create a hazardous drug (HD) list Train staff and implement usage of safety data sheets Determine storage requirements for HDs Perform an assessment of risk where applicable Review PPE requirements What equipment is necessary? Shipping/transport/disposal 19
20 Harder things to do: Non sterile facility requirements: Harder things to do: Sterile facility requirements: 20
21 Where to begin? Be familiar with <800> and current NIOSH publication (2016) Prepare and train staff Create a hazardous drug list Assess facilities compliant for services offered? Or Jon Pritchett, Pharm.D., RPh. Associate Director, Pharmacy Accreditation Commission for Healthcare jpritchett@achc.org
Statement of Ronna B. Hauser, Pharm.D. Vice President, Pharmacy Affairs National Community Pharmacists Association
Statement of Ronna B. Hauser, Pharm.D. Vice President, Pharmacy Affairs National Community Pharmacists Association Food and Drug Administration [Docket No. FDA 2017 N 1847] Pharmacy Compounding Advisory
More informationCompounding Pharmacy Pharmacy s Past, Present & Future
Compounding Pharmacy Pharmacy s Past, Present & Future David G. Miller, RPh Executive Vice President & CEO International Academy of Compounding Pharmacists 1 Compounding Pharmacy Pharmacy s Past, Present
More informationTSDR Pharmacy Inc. dba brandmd Skin Care 11/9/17
TSDR Pharmacy Inc. dba brandmd Skin Care 11/9/17 Division of Pharmaceutical Quality Operations IV 19701 Fairchild, Irvine, CA 92612-2506 Telephone: 949-608-2900 Fax: 949-608-4417 WARNING LETTER VIA SIGNATURE
More informationStonegate Pharmacy LP 11/10/16
Stonegate Pharmacy LP 11/10/16 November 10, 2016 2017 DAL WL 03 WARNING LETTER UPS Overnight Rene F. Garza, Pharm.D., Chief Executive Officer Stonegate Pharmacy, LP 2501 W. William Cannon Drive, Suite
More information720 cases. 20 states. Conflict of Interest Declaration. New England Compounding Center (NECC) timeline. (NECC) timeline (continued) 3/28/2013
Conflict of Interest Declaration Compounding at a Crossroads: The Federal and State Outlook Christopher J. Topoleski has no actual or potential conflicts of interest in relation to this activity Christopher
More informationGuidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry DRAFT GUIDANCE This guidance
More informationLegislative and Regulatory Update Michael Baxter APhA Director, Regulatory Affairs
Legislative and Regulatory Update 2018 Michael Baxter APhA Director, Regulatory Affairs 1 CPE Information and Disclosures Michael Baxter declares no conflicts of interest, real or apparent, and no financial
More informationHieber's Pharmacy 12/5/17
Hieber's Pharmacy 12/5/17 Division of Pharmaceutical Quality Operations I 10 Waterview Blvd, 3rd FL Parsippany, NJ 07054 Telephone: (973) 331-4900 FAX: (973) 331-4969 CERTIFIED MAIL RETURN RECEIPT REQUESTED
More informationSan Diego Compounding Pharmacy 9/25/17
San Diego Compounding Pharmacy 9/25/17 Division of Pharmaceutical Quality Operations IV 19701 Fairchild Road Los Angeles, CA 92612 WARNING LETTER VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED September
More informationTown and Country Compounding and Consultation Services, LLC 10/17/17
Town and Country Compounding and Consultation Services, LLC 10/17/17 Division of Pharmaceutical Quality Operations I 10 Waterview Blvd, 3rd FL Parsippany, NJ 07054 Telephone: (973) 331-4900 FAX: (973)
More informationTalon Compounding Pharmacy 10/3/17
Talon Compounding Pharmacy 10/3/17 Office of Pharmaceutical Quality Operations, Division II 4040 N. Central Expressway, Suite 300 Dallas, Texas 75204 October 3, 2017 CMS Case # 522630 VIA UPS EXPRESS WARNING
More informationOverview of FDA Oversight and Enforcement on Drug Compounding
Overview of FDA Oversight and Enforcement on Drug Compounding Ruey Ju, Pharm.D., J.D. Senior Advisor for Compounding Compliance and Enforcement (Acting) Center for Drug Evaluation and Research Today s
More informationQuality. Guaranteeing High Quality. Outsourced Pharmacy Services. Disclosure 3/18/2013
Disclosure Outsourced Pharmacy Services By: Eddie Bostic, RPh For: South Carolina Society of Health System Pharmacist Annual Meeting, March 24 th 2013 Charleston, SC The views and opinions expressed in
More informationHEB Pharmacy Conference October 25, 2014
Texas State Board of Pharmacy Laws and Rules Update Allison Benz, R.Ph., M.S. Director of Professional Services Central Texas Society of Health-System Pharmacists Annual Seminar October 25, 2014 Texas
More informationUSP <797> Overview and Compliance Audit Results. Joseph W. Coyne RPh Director of Field Operations Clinical IQ, LLC
USP Overview and Compliance Audit Results Joseph W. Coyne RPh Director of Field Operations Clinical IQ, LLC Acknowledgements Many of the slides presented in this program come from the CriticalPoint
More informationperpetuate -- and perhaps even intensify -- that controversy. 1 On July 18th, the Fifth Circuit affirmed FDA s longstanding position that
Food & Drug July 29, 2008 Fifth Circuit Rules that FDA May Regulate Compounded Drugs as New Drugs Update on Medical Center Pharmacy v. Mukasey For decades, the pharmacy compounding industry has disputed
More informationBusiness Impact Analysis
ACTION: Original DATE: 05/01/2018 10:55 AM Business Impact Analysis Agency Name: Ohio Department of Health Regulation/Package Title: Chapter 3701-52 Smoke Free Workplace Rule Number(s): 3701-52 Date: November
More informationFACT SHEET: Federal Parity Task Force Takes Steps to Strengthen Insurance Coverage for Mental Health and Substance Use Disorders
The White House Office of the Press Secretary For Immediate Release October 27, 2016 FACT SHEET: Federal Parity Task Force Takes Steps to Strengthen Insurance Coverage for Mental Health and Substance Use
More informationUS H.R.6 of the 115 th Congress of the United States Session
US H.R.6 of the 115 th Congress of the United States 2017-2018 Session This Act may be cited as the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities
More informationFebruary 3, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852
February 3, 2014 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 [Submitted electronically to www.regulations.gov] Re: Draft Guidance;
More informationCompare Results. 153 Replacements 26 Insertions 344 Deletions. Total Changes. Styling and. Content. 0 Annotations. Old File: New File:
3/1/2019 4:12:31 PM Compare Results Old File: Draft Guidance.pdf 20 pages (438 KB) 3/21/2018 3:55:17 PM versus New File: Final Guidance.pdf 21 pages (323 KB) 2/28/2019 11:42:05 AM Total Changes 523 Text
More informationProposition 65 and Supplements
Proposition 65 and Supplements Nutrition Industry Association John Venardos Senior Vice President Worldwide Regulatory & Government Affairs Herbalife International of America, Inc. 5/23/2011 SYNOPSIS Now
More informationGuidance for Municipalities Regarding Marijuana for Adult Use January 2018
Guidance for Municipalities Regarding Marijuana for Adult Use January 2018 The following information is provided to assist municipalities by addressing questions related to the regulation of marijuana
More informationPRESERVING PATIENT ACCESS TO COMPOUNDED MEDICATIONS H.R. 2871
PRESERVING PATIENT ACCESS TO COMPOUNDED MEDICATIONS H.R. 2871 BACKGROUND: Compounded medications are used to treat patients with unique medical conditions that make them resistant to standard medications.
More informationBackground. Historical Context
Background In order to use prescription medications safely, consumers need to receive clear, actionable information. This medication information must be accurate, balanced, and delivered in a consistent
More informationTeva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044
DEPARTMENT OF HEALTH & HUMAN SERVICES ANDA 090783 Food and Drug Administration Silver Spring, MD 20993 Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs
More information2016 Dr. Douglas H. Kay CPE Symposium
GREGORY CAMERON, R.Ph ASSISTANT PROFESSOR OF PHARMACY PRACTICE FIELD COORDINATOR COMMUNITY SITES HUSSON UNIVERSITY SCHOOL OF PHARMACY November 5, 2016 Please Silence All Electronic Equipment OBJECTIVES
More informationRE: Permits under the Arizona Pharmacy Act should not be required for dietary supplements
Board Members Arizona State Board of Pharmacy 1616 W. Adams St., Suite 120 Phoenix, AZ 85007 c/o Kam Gandhi, PharmD Executive Director Arizona State Board of Pharmacy Via email: kgandhi@azpharmacy.gov
More informationTRAUMA RECOVERY/HAP OPERATING GUIDELINES
TRAUMA RECOVERY/HAP OPERATING GUIDELINES FOR THE NATIONAL TRAUMA RECOVERY NETWORK, THE TRAUMA RECOVERY NETWORK ASSOCIATIONS, AND THE TRAUMA RECOVERY NETWORK CHAPTERS Operating Guidelines These Operating
More informationTexas Vendor Drug Program Specialty Drug List Process. February 2019
Texas Vendor Drug Program Specialty Drug List Process February 2019 Table of Contents Table of Contents...1 1 About the Specialty Drug List...2 1.1 Information for Pharmacies... 2 1.2 Information for Managed
More informationMarijuana Legalization Update
Marijuana Legalization Update PJ McCann, Esq. Deputy General Counsel February 14, 2018 1 Context Many moving parts in Cannabis Control Commission (CNB) regulatory process Information and recommendations
More informationThe proposed rule is significant, and the requirements and exceptions are complex. Key provisions of the proposal are described below.
ADVISORY Food & Drug FDA ISSUES PROPOSED RULE TO ESTABLISH A UNIQUE DEVICE IDENTIFICATION SYSTEM FOR MEDICAL DEVICES July 16, 2012 On July 11, 2012, the Food and Drug Administration (FDA) published in
More informationFDLI s Enforcement, Litigation, and Compliance Conference. Center for Tobacco Products Office of Compliance and Enforcement 2017 Update
FDLI s Enforcement, Litigation, and Compliance Conference Center for Tobacco Products Office of Compliance and Enforcement 2017 Update Ann Simoneau, Director Office of Compliance and Enforcement Center
More informationFood Safety Modernization Act - Impacts on the Grain and Feed Industry
Food Safety Modernization Act - Impacts on the Grain and Feed Industry NGFA 117th Annual Meeting and Convention March 17, 2013 San Francisco, California David Fairfield, NGFA Vice President of Feed Services
More informationAMTA Government Relations Overview
AMTA Government Relations Overview Why license the massage therapy profession? Under U.S. law authority rests with states to regulate professions that have an impact on the health, safety and welfare of
More informationPlanning For The FDA s 'Deeming Rule' For E- Cigarettes
Law360, New York (September 21, 2015, 3:39 PM ET) -- The 2009 Family Smoking Prevention and Tobacco Control Act (TCA)[1] gave the U.S. Food and Drug Administration the authority to oversee the manufacture,
More informationDRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT
c t DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to September 22, 2014. It is intended
More informationThe FDA Food Safety Modernization Act: The Key New Requirements
June 15, 2011 The FDA Food Safety Modernization Act: The Key New Requirements Executive Summary INSTITUTE FOR FOOD LAWS & REGULATIONS Michigan State University 140 G.M. Trout Building East Lansing, MI
More informationAgency Information Collection Activities; Submission for Office of Management and Budget
This document is scheduled to be published in the Federal Register on 01/28/2016 and available online at http://federalregister.gov/a/2016-01690, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationFood Labeling: Revision of the Nutrition and Supplement Facts Labels and Serving Sizes of
This document is scheduled to be published in the Federal Register on 10/02/2017 and available online at https://federalregister.gov/d/2017-21019, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationChanges to the Eighth Edition
Pharmacy Practice and the Law, Eighth Edition Includes Navigate 2 Advantage Access By Richard R. Abood, BS Pharm, JD-Professor Emeritus Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences,
More informationGeneric Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public Hearing;
4160-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 15 [Docket No. FDA-2013-N-0402] Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public
More informationFacilitate physician access to compounded drugs for office-use from 503A compounding pharmacies for patients with emergent conditions;
By Electronic Delivery Scott Gottlieb, MD Commissioner Food and Drug Administration Attn: Division of Dockets Management (HFA-305) 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: FDA-2017-N-5093 for
More informationSTATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A.
STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A. Arizona Corporate Counsel Presentation May 8, 2018 Agenda 1. Overview of the Opioid
More informationGAO. PRESCRIPTION DRUGS State and Federal Oversight of Drug Compounding by Pharmacies
GAO For Release on Delivery Expected at 10:00 a.m. Thursday, October 23, 2003 United States General Accounting Office Testimony Before the Committee on Health, Education, Labor, and Pensions, U.S. Senate
More informationThe Sale of Cannabis in Pharmacies. Michael H. Ghobrial, PharmD, JD Associate Director, Health Policy American Pharmacists Association
The Sale of Cannabis in Pharmacies Michael H. Ghobrial, PharmD, JD Associate Director, Health Policy American Pharmacists Association Development This activity was developed by the American Pharmacists
More informationSUBJECT: Effective Date: Policy Number: Controlled Substance and Prescription Drugs 11/30/
Division of Research SUBJECT: Effective Date: Controlled Substance and Prescription Drugs 11/30/2018 Supersedes: Page Of 12/04/2015 04/25/2007 1 6 Responsible Authorities: Vice President, Research Institutional
More informationSUPPLEMENTAL NOTE ON HOUSE BILL NO. 2217
SESSION OF 2017 SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2217 As Amended by House Committee on Health and Human Services Brief* HB 2217, as amended, would enact new law and amend the Kansas Pharmacy Act (Act)
More information116th Annual Convention
116th Annual Convention Date: Monday, October 20, 2014 Time: 8:00 am 9:30 am Location: Austin Convention Center, Room 17AB, Level 4 Title: Activity Type: Speaker: Compounding - Important Developments That
More informationThe Radiation Health and Safety Act, 1985
1 The Radiation Health and Safety Act, 1985 Repealed by Chapter S-15.1 of the Statutes of Saskatchewan, 2013 (effective April 29, 2014) Formerly Chapter R-1.1 of the Statutes of Saskatchewan, 1984-85-86
More informationSUMMARY: The Food and Drug Administration (FDA) is requesting public input on updated
This document is scheduled to be published in the Federal Register on 11/22/2017 and available online at https://federalregister.gov/d/2017-25245, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationRULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS
RULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER 1140-17 DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS 1140-17-.01 Definitions 1140-17-.02 Purpose 1140-17-.03 Eligibility Criteria for Program Participation
More informationBoard of Pharmacy Update
Board of Pharmacy Update Gay Dodson, R.Ph. Executive Director/Secretary Texas Pain Society s 6 th Annual Scientific Meeting October 26, 2014 Goals Review some recent changes to federal law. Review some
More informationSubtitle E--National Bioengineered Food Disclosure Standard
GMO Labeling Bill S.764 as of July 14, 2016* [Congressional Bills 114th Congress] [From the U.S. Government Publishing Office]* [S. 764 Enrolled Bill (ENR)] S.764 One Hundred Fourteenth Congress of the
More informationCurrent through Chapter 199 and Chapters of the 2015 Legislative Session
26-21-101. Short title. 26-21-101. Short title This article shall be known and may be cited as the "Colorado Commission for the Deaf and Hard of Hearing Act". Cite as C.R.S. 26-21-101 History. L. 2000:
More informationHistory Note: Authority G.S ; ; ; Eff. May 1, 1997; Amended Eff. January 1, 2015; March 1, 2013.
21 NCAC 46.1412 PHYSICAL REQUIREMENTS A health care facility pharmacy shall have sufficient floor space allocated to it to ensure that drugs are prepared in sanitary, well lighted, and enclosed places.
More informationJuly 3, Re: Proposed Rule: National Bioengineered Food Disclosure Standard. 83 FR (May 4, 2018). Docket No. AMS-TM
July 3, 2018 VIA ELECTRONIC SUBMISSION Agricultural Marketing Service Docket Clerk 1400 Independence Ave. SW Room 4543-South Washington, DC 20250 Re: Proposed Rule: National Bioengineered Food Disclosure
More informationOpioid Policy Steering Committee: Prescribing Intervention--Exploring a Strategy for
This document is scheduled to be published in the Federal Register on 12/13/2017 and available online at https://federalregister.gov/d/2017-26785, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationRaritan Pharmaceuticals, Inc. 6/20/17
Raritan Pharmaceuticals, Inc. 6/20/17 U.S. Food & Drug Administration Division of Pharmaceutical Quality Operations I New Jersey District 10 Waterview Boulevard, 3rd Floor Parsippany, NJ 07054 June 20,
More informationCompounding Sterile Drugs: A Regulatory Update
Compounding Sterile Drugs: A Regulatory Update Fred Massoomi, Pharm.D., FASHP Senior Director Visante, Inc. March 21, 2017 Copyright Visante, Inc. 2017 www.visanteinc.com 1 Objectives Review incidents
More information2014 FDA/JIFSAN Food & Nutrition Webinar
2014 FDA/JIFSAN Food & Nutrition Webinar Medical Foods Shawne Suggs-Anderson, MMSc, _ RD Infant Formula and Medical Foods Staff ONLDS/CFSAN/FDA September 23, 2014 53 Main Objectives History What is a Medical
More informationHealth Authority Abu Dhabi. Document Title: Policy for Recall of Drugs and Healthcare Products Document Ref. Number:
Health Authority Abu Dhabi Document Title: Policy for Recall of Drugs and Healthcare Products Document Ref. Number: PPR/DMP/DR/P0001 Version 0.9 Approval Date: August 2007 Effective Date: August 2007 Last
More informationISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy, Albuquerque, NM. [ NMAC - N, ; A, ]
TITLE 16 CHAPTER 19 PART 26 OCCUPATIONAL AND PROFESSIONAL LICENSING PHARMACISTS PHARMACIST PRESCRIPTIVE AUTHORITY 16.19.26.1 ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy, Albuquerque,
More information6/7/2017 CHANGES IN PHARMA REGULATIONS HOW IT AFFECTS THE OR NURSE DISCLOSURE OBJECTIVES
CHANGES IN PHARMA REGULATIONS HOW IT AFFECTS THE OR NURSE John Karwoski, RPh, MBA DISCLOSURE I, John Karwoski, RPH, MBA have business relationships with the companies MOBIUS THERAPEUTICS, LLC, Cubex, and
More informationWhat Do IACP Members Think?
What Do IACP Members Think? Results of a National Survey of Compounding Practitioners February 27, 2013 Final Summary Results What Do Compounders Think? National Survey of 2,857 pharmacists and technicians
More informationRisk Evaluation And Mitigation Strategies:
Risk Evaluation And Mitigation Strategies: The Experts Answer Questions from Health-System Pharmacists A midday symposium about the risk evaluation and mitigation strategies (REMS) required by the Food
More informationApril 25, 2014 Reference No. HAMB FDA Transparency Initiative Regulations Development
Reference No. HAMB14001 Via Email Dr. Margaret Hamburg Commissioner U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 margaret.hamburg@fda.hhs.gov SUBJECT: FDA Transparency
More informationPLEASE NOTE. For more information concerning the history of this Act, please see the Table of Public Acts.
PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to July 1, 2012. It is intended for information and reference purposes only. This
More informationMIAMI CHILDREN S HOSPITAL POLICY AND PROCEDURE
ISSUED BY: Research PAGE: 1 of 6 REPLACES POLICY DATED: EFFECTIVE DATE: 08/09/2012 DISTRIBUTION: Departmentwide APPROVED BY: Andrews, April (SVP/CECO), BOD Audit and Compliance Committee, Perdomo, Jose
More informationAn Epic Battle Pharmacist Heroes vs. Shortages
An Epic Battle Pharmacist Heroes vs. Shortages Erin R. Fox, PharmD, BCPS, FASHP Twitter: @foxerinr mmpharmd Disclosure This presentation represents my own opinions. University of Utah Drug Information
More informationThree-Month Extension of Certain Tobacco Product Compliance Deadlines Related to the
This document is scheduled to be published in the Federal Register on 05/15/2017 and available online at https://federalregister.gov/d/2017-09754, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationMunicipal Guidance CONTACTING THE COMMISSION. 101 Federal Street, 13 th Floor Boston, MA Phone: (617) Fax: (617)
Municipal Guidance UPDATED MARCH, 2018 The following information is provided to assist municipalities by addressing questions related to the regulation of marijuana establishments. Additional information
More informationSENATE, No STATE OF NEW JERSEY. 218th LEGISLATURE INTRODUCED FEBRUARY 5, 2018
SENATE, No. STATE OF NEW JERSEY th LEGISLATURE INTRODUCED FEBRUARY, 0 Sponsored by: Senator JEFF VAN DREW District (Atlantic, Cape May and Cumberland) SYNOPSIS Compounding Pharmacy Quality Assurance Act
More informationOverview of Dietary Supplement GMP Inspection Trends Quality Session 6
Overview of Dietary Supplement GMP Inspection Trends Quality Session 6 Presented by: Dean R. Cirotta, MBA President & Chief Operating Officer EAS Consulting Group, LLC 1700 Diagonal Road, Suite 750 Alexandria,
More informationSchedules of Controlled Substances: Placement of Furanyl fentanyl, 4- Fluoroisobutyryl fentanyl, Acryl fentanyl, Tetrahydrofuranyl fentanyl, and
This document is scheduled to be published in the Federal Register on 11/29/2018 and available online at https://federalregister.gov/d/2018-26045, and on govinfo.gov Billing Code 4410-09-P DEPARTMENT OF
More informationWithdrawal of Proposed Rule on Supplemental Applications Proposing Labeling Changes for
This document is scheduled to be published in the Federal Register on 12/14/2018 and available online at https://federalregister.gov/d/2018-27098, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND
More informationPolling Question # 3. DISCLOSURE STATEMENT Pharmacy Immunizations How to Stay Competitive and in Compliance LEARNING OBJECTIVES
DISCLOSURE STATEMENT Pharmacy Immunizations How to Stay Competitive and in Compliance R. JEFFREY HEDGES President & CEO I, Jeff Hedges, disclose that I am employed as a consultant at R.J. Hedges & Associates.
More informationADMINISTRATIVE POLICY AND PROCEDURES MedStar Family Choice Medicare Advantage Plans
ADMINISTRATIVE POLICY AND PROCEDURES MedStar Family Choice Medicare Advantage Plans DEPARTMENT: Medicare Compliance POLICY TITLE: RELATED DEPARTMENTS: All POLICY #: 700C VERSION #: 3 REVISION DATE: Medicare
More informationInterstate Interfacility Transport of a Patient with
Interstate Interfacility Transport of a Patient with Tabletop Exercise The gives elected and appointed officials, observers, media personnel, and players from participating organizations information they
More informationPolicy / Drug and Alcohol-Free Workshops
Policy 4118.235/4218.235 Drug and Alcohol-Free Workshops DATE: February 13, 2017 PREVIOUS ITEM: None ENCLOSURES: CABE s Suggested Policy 4118.235/4218.235 CABE s July 15, 2016 Policy Update REASON: To
More informationHome Model Legislation Public Safety and Elections. Methamphetamine Reduction Act
Search GO LOGIN LOGOUT HOME JOIN ALEC CONTACT ABOUT MEMBERS EVENTS & MEETINGS MODEL LEGISLATION TASK FORCES ALEC INITIATIVES PUBLICATIONS NEWS Model Legislation Home Model Legislation Public Safety and
More informationCommercial Feed Mill Verification Task Procedures
Introduction The Canadian Food Inspection Agency (CFIA) is dedicated to safeguarding food, animals and plants, which enhances the health and well-being of Canada s people, environment and economy. As part
More informationAgency Information Collection Activities; Submission for Office of Management and
This document is scheduled to be published in the Federal Register on 03/04/2019 and available online at https://federalregister.gov/d/2019-03824, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND
More informationSubstitute HB 523 Outline
Substitute HB 523 Outline 1. Creates Medical Marijuana Control Commission under the auspice of the Department of Commerce 9 member commission No more than 4 members of the Commission shall be from 1 political
More informationNew England Compounding Center 04-Dec-06
New England Compounding Center 04-Dec-06 Department of Health and Human Services Public Health Service Food and Drug Administration New England District One Montvale Avenue Stoneham, Massachusetts 02180
More informationRe: Implementation of the Federal Tamper-Resistant Prescription Pad Mandate
January 2, 2008 Ms. Carol Herrmann-Steckel Commissioner Alabama Medicaid Agency PO Box 5624 501 Dexter Avenue Montgomery, AL 36103-5624 Re: Implementation of the Federal Tamper-Resistant Prescription Pad
More informationMitch Zeller, Director, Center for Tobacco Products, FDA September 19, 2013 Kansas Public Health Association
Regulatory Public Laws Compliance & Education Policies Science & Enforcement & Communications The FDA Center for Tobacco Products (CTP): Its Role in Reducing Tobacco Use Mitch Zeller, Director, Center
More informationTitle 32: PROFESSIONS AND OCCUPATIONS
Title 32: PROFESSIONS AND OCCUPATIONS Chapter 45-A: PHYSICAL THERAPIST PRACTICE ACT Table of Contents Section 3111. DEFINITIONS... 3 Section 3111-A. SCOPE OF PRACTICE... 3 Section 3112. BOARD CREATED;
More informationBOARD OF PHARMACY- REGULATORY UPDATE. Kimberly Grinston, J.D., Executive Director
BOARD OF PHARMACY- REGULATORY UPDATE Kimberly Grinston, J.D., Executive Director Disclosure and Conflict of Interest I declare no conflicts of interest, real or apparent, and no financial interest in any
More informationSub. S.B. 119 As Passed by the Senate
AM3404 Sub. S.B. 119 As Passed by the Senate Topic: Opioid Data and Communication Expansion Act moved to amend as follows: In line 1 of the title, after "4723.52," insert "4729.01, 4729.44, 4729.75, 4729.79,
More informationMinnesota Board of Dentistry
This document is made available electronically by the Minnesota Legislative Reference Library as part of an ongoing digital archiving project. http://www.leg.state.mn.us/lrl/sonar/sonar.asp Minnesota Board
More informationSlow The Old FDA Entangled in its own bureaucracy Alleged by some to be too friendly with the industry it was supposed to regulate 3 What is the Curre
HCCA Research Compliance Conference What Every Compliance Professional Should Know About Dealing With The FDA Neil F. O Flaherty OFW Law June 13, 2011 1 Key Take-Aways Insights into what s going on at
More information4/26/2018. Bureau of Professional Licensing. MAPS Updates & Opportunities. MAPS Background. Registration. MAPS Update
Bureau of Professional Licensing MAPS Updates & Opportunities April 28, 2018 Presented by Andrew Hudson, Manager Haley Winans, Analyst Drug Monitoring Section Bureau of Professional Licensing BPL-MAPS@Michigan.gov
More informationLeadingAge and Hospice Members: Partners in Providing Quality Care to Older Adults. January 2019
LeadingAge and Hospice Members: Partners in Providing Quality Care to Older Adults January 2019 Hospice is a unique service delivery model providing holistic care to individuals at the end of their lives.
More informationliterature that drug combinations containing butalbital should not be used in treatment of chronic pain and are not appropriate for long term routine
ACTION: Original BIA p(111397) pa(192459) d: (446870) DATE: 09/16/2013 2:14 PM print date: 04/02/2019 9:58 PM 1. Limit reimbursement for sedative hypnotic agents to the following medications: zolpidem
More informationNCPA LTC Division Newsletter
March 2016 NCPA LTC Division Newsletter NCPA Offers FDA Additional Information on Repackaging Draft Guidance NCPA recently joined with the American Society of Consultant Pharmacists (ASCP) in a follow
More informationELECTIONS APPLICATION FORM WPHNA Executive Committee
ELECTIONS 2017 APPLICATION FORM WPHNA Executive Committee This is the Application form for the 2017 WPHNA Elections. All queries about positions, the election process, or any other relevant matter, should
More informationDecember 4, 2017 VIA ELECTRONIC SUBMISSION
VIA ELECTRONIC SUBMISSION December 4, 2017 Dockets Management Staff (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Development of a List of pre-dietary Supplement
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Apini$r$iy -tq 5-f
DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Apini$r$iy -tq 5-f J Dallas District 4040 North Central Expressway Dallas, Texas 75204-3145 Ref: 2004-DAL-WL-03 WARNING LETTER CERTIFIED MAIL RETURN
More information